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Abstract
Background—The rate of overdose deaths caused by fentanyl-contaminated heroin (FCH) use is 
increasing rapidly in the United States. We examined risk factors for exposure to FCH and 
experiences with FCH use among young adult non-medical prescription opioids (NMPO) users.
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Methods—We analyzed data from the Rhode Island Young Adult Prescription Drug Study 
(RAPiDS), which enrolled young adults aged 18 to 29 reporting prior 30 day NMPO use between 
January 2015 and February 2016. Participants completed questionnaires ascertaining drug use 
patterns and risk behaviors, including FCH exposure. Logistic regression was used to assess 
factors associated with known or suspected FCH exposure.
Results—Of 199 participants, the median age was 25 (IQR: 22, 27), 130 (65.3%) were male, and 
122 (61.3%) were of white, non-Hispanic race/ethnicity. In total, 22 (11%) reported known or 
suspected FCH exposure in the prior six months. Several drug use patterns and risk behaviors were 
associated with FCH exposure, including: regular heroin and cocaine use; diverted pharmaceutical 
fentanyl use in the prior six months; NMPO use to avoid withdrawal symptoms; longer duration of 
NMPO use; injection drug use; and prior overdose (all p<0.001). Among participants who 
reported 3 FCH exposure, 59% were unaware that their heroin was contaminated with fentanyl 
prior to last use, 59% reported that FCH provides a better high, and all recognized that fentanyl 
increases overdose risk.
Conclusions—Exposure to fentanyl-contaminated heroin is an emerging trend among young 
adult NMPO users in Rhode Island. Overdose prevention programs addressing FCH use are 
urgently needed.
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1. INTRODUCTION
Opioid use disorder and opioid overdose are escalating epidemics in the United States. From 
2000 to 2014, the rate of opioid-involved overdose deaths increased by 200% (Rudd, 
Aleshire, Zibbell, & Gladden, 2016). During this period, non-medical prescription opioid 
(NMPO) use was a driver of overdose-related mortality (Calcaterra, Glanz, & Binswanger, 
2013). However, more recent national data suggest shifting trends, with heroin-involved 
overdose deaths increasing more than three-fold between 2010 and 2014 (Compton, Jones, 
& Baldwin, 2016).
Across the US, and particularly in New England, rates of fatal overdose have been 
exacerbated by fentanyl-contaminated heroin (FCH) and other forms of illicit fentanyl use 
(Centers for Disease Control and Prevention, 2015). From 2013 to 2014, overdose death 
rates involving synthetic opioids (including fentanyl) increased 80% (Rudd et al., 2016). In 
2015, half of all overdose deaths in Rhode Island involved fentanyl and fentanyl analogs—
an increase from 37% in 2014 and less than 5% in the years prior to 2014 (Rhode Island 
Governor's Overdose Prevention and Intervention Task Force, 2015). Eighty-six fentanyl 
deaths occurred in Maine in 2015, up from only 2 in 2013 (Sorg, Greenwald, & Wren, 
2016), and fentanyl was attributed to five times as many deaths as heroin in 2015 in New 
Hampshire (2016). Given this emerging crisis, there is an urgent need to identify persons 
who may be at risk for fentanyl-related overdose and to understand users’ experiences with 
FCH.
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The purpose of this study was to identify correlates of self-reported use of heroin that is 
known or suspected to have been adulterated with fentanyl (hereafter referred to as FCH 
exposure) and to examine users’ experiences with FCH. To the authors’ knowledge, this 
study is among the first to explore correlates of FCH exposure and examine firsthand 
experiences with and attitudes toward FCH among young adults in the US.
2. MATERIALS AND METHODS
2.1 Study design and sample
The data analyzed here were collected as a part of a pilot study that assessed the patterns and 
determinants of NMPO use among young adults. From January 2015 to February 2016, the 
Rhode Island Young Adult Prescription Drug Study (RAPiDS) recruited 200 Rhode Island 
residents aged 18–29 who endorsed prior-30-day NMPO use. Participants were compensated 
$25 for their time. This study was approved by the Institutional Review Board (IRB) at 
Brown University.
Participants were recruited through a combination of targeted canvassing, snowball 
sampling, and internet-based recruitment from online classifieds, drug information websites, 
and social media. Throughout the recruitment period, paper recruitment flyers were placed 
in and distributed from Rhode Island-based substance use treatment centers, recovery 
support centers, urgent care centers, and service agencies (e.g., syringe exchange programs); 
street canvassing was also utilized in major Rhode Island cities.
Snowball sampling methods were utilized in the first recruitment phase. During this phase, 
each participant was asked to refer up to two eligible peers. For referrals that were 
redeemed, the referring participant received one $5 gift card via mail or in person. Referred 
participants were also invited to refer their peers to the study, and so forth, until several 
recruitment chains were produced.
Internet-based recruitment methods were utilized in the second recruitment phase. 
Participants were recruited from online classified sites (e.g., Craigslist), drug information 
sites (e.g., Bluelight.org), and social media sites (e.g., Facebook). Search engine-based 
banner advertising was also used to target Rhode Island-based individuals searching relevant 
terms (e.g., opioid, pills).
Participants were interviewed individually by trained personnel in private settings. 
Computer-assisted personal interviewing (CAPI) was used to collect socio-demographic data 
and drug use patterns; computer-assisted self-interviewing (CASI) was used to collect 
particularly sensitive or stigmatizing information (e.g., injection drug use).
2.2 Measures
2.2.1 Non-medical fentanyl use—All participants were asked whether they had ever 
engaged in non-medical fentanyl use, defined as use “without a doctor’s orders or not as a 
doctor directed”. Participants who endorsed lifetime non-medical fentanyl use were asked 
which formulations of fentanyl they had used in the prior six months. Response options 
included “skin patch”, “pills”, “nasal spray”, “lozenge/lollipop”, “a film that dissolves under 
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your tongue”, and “fentanyl-laced heroin”. Participants who endorsed this last option were 
considered as having known or suspected FCH exposure in the prior six months; an 
affirmative answer to any other response option was defined as any diverted fentanyl use in 
the prior six months. Those who endorsed FCH use were asked whether—at their most 
recent use of FCH—they were aware of fentanyl contamination prior to use. We also 
assessed frequency of FCH use in the prior six months (response options were “never”, 
“once or a couple of times”, “about once a month”, “at least every week”, and “every day”), 
and we solicited experiences with and attitudes toward FCH. Covariates of interest were 
socio-demographic characteristics, drug use patterns and risk behaviors, and clinical factors.
2.2.2 Socio-demographic characteristics—We assessed age, male sex at birth, race/
ethnicity (categorized as white, non- Hispanic vs. other), educational attainment beyond high 
school, as well as lifetime history of detainment in a jail/prison and homelessness.
2.2.3 Risk behaviors and drug use patterns—Drug use patterns assessed included 
regular use of heroin, NMPO use, cocaine use, injection drug use, and non-medical 
benzodiazepine use, which we defined as weekly or greater in the prior six months. Non-
medical prescription drug use was defined as use “without a doctor’s orders or not as a 
doctor directed,” and to improve measurement validity, the images and brand names of 
several prescription opioids (e.g., Vicodin, OxyContin) and benzodiazepines (e.g., Xanax, 
Valium) were included in the assessment. Participants reported their duration of NMPO use 
(in years), as well as whether they primarily use prescription opioids to avoid withdrawal 
symptoms. We also assessed lifetime history of witnessing and experiencing an overdose.
2.2.4 Clinical factors—We examined history of any mental health diagnosis, self-reported 
positive hepatitis C virus (HCV) status among those who had ever tested for HCV, and 
whether participants had ever been prescribed an opioid.
2.3. Statistical analyses
Given the low prevalence of FCH exposure in the sample, bivariable logistic regression was 
used to assess factors associated with the outcome. Descriptive statistics were generated to 
characterize experiences with and attitudes toward FCH. One participant was excluded due 
to missing data. Statistical analyses were conducted using SAS version 9.4. All p-values are 
two-sided.
3. RESULTS
Among the 199 participants who were included in these analyses, the majority was male 
(65.3%), and the median age was 25 (interquartile range [IQR]: 22–27). While the majority 
was white/non-Hispanic (61.3%), collectively, a substantial fraction of the sample was black 
(16.6%), multi-racial (15.1%), or ethnically Latino/a (14.1%). The prevalence of FCH 
exposure in the prior six months was 11.1% (n=22). Along with age, white race/ethnicity, 
and lifetime homelessness, FCH exposure was significantly associated with several drug use 
patterns and risk behaviors, including: regular heroin and cocaine use; regular injection drug 
use, diverted pharmaceutical fentanyl use in the prior six months; regular non-medical 
benzodiazepine use, NMPO use primarily to avoid withdrawal symptoms; and longer 
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duration of NMPO use (all p<0.05, see Table 1). The majority of participants reporting FCH 
exposure had ever experienced an overdose (63.6%), compared to only 22.0% of non-
exposed participants (unadjusted odds ratio=6.2, 95%CI: 2.4–15.8). All but one participant 
reporting FCH exposure had ever witnessed an overdose. Self-reported positive HCV status 
was also associated with FCH exposure in the prior six months (see Table 1).
Among those who reported FCH exposure in the prior six months, when asked about their 
most recent suspected exposure to FCH, 13 (59%) reported being unaware that the heroin 
was contaminated with fentanyl prior to use (i.e., were told that their drugs contained 
fentanyl after use or suspected exposure based on their reaction to the drug); 8 (36%) 
reported being aware that the heroin was contaminated with fentanyl prior to use, and 1 (5%) 
was unsure. Three (14%) reported daily use of FCH and 8 (36%) reported using FCH “at 
least every week.”
Attitudes toward FCH varied. Among participants who reported FCH exposure, 14 (64%) 
reported that they were confident that they could distinguish FCH from heroin that is not 
contaminated with fentanyl; 8 (36%) reported that they were not confident or unsure. 
Among those who were unaware that their heroin was contaminated with fentanyl prior to 
use, 6 (46%) agreed or strongly agreed that FCH provides a better high than heroin that is 
not contaminated with fentanyl; among those who were aware, 7 (88%) agreed or strongly 
agreed that FCH provides a better high (p=0.174). Altogether, 59% (n=13) reported that 
FCH provides a better high. All participants either agreed (n=3, 14%) or strongly agreed 
(n=19, 86%) that fentanyl contamination increases overdose risk.
4. DISCUSSION
The present study is among the first to explore correlates of FCH use and report firsthand 
experiences with and attitudes toward FCH among young adults in the US. Among young 
adult NMPO users, those who endorsed FCH use typically reported greater and more 
extensive drug use experiences, as evidenced by more frequent and longer durations of drug 
use, injection drug use, greater endorsement of risk behaviors, and worse health outcomes 
(e.g., self-reported HCV positive status). The majority reported being unaware that their 
heroin was contaminated with fentanyl at their most recent use, and those who were aware 
were more likely to report that FCH provides a better high. All participants acknowledged 
that fentanyl contamination increases overdose risk.
Correlates of FCH use have not been previously explored among young adults in the US; 
however, our findings are consistent with research examining factors associated with non-
fatal overdose among young people who use opioids non-medically. Several factors 
identified in previous studies as correlates of non-fatal overdose were significantly 
associated with FCH use in the present study, including white racial background (Sherman, 
Cheng, & Kral, 2007), longer duration of drug use (Schrager et al., 2014; Sherman et al., 
2007), regular non-medical benzodiazepine use and heroin use (Silva, Schrager, Kecojevic, 
& Lankenau, 2013), and injection drug use (Mitra, Wood, Nguyen, Kerr, & DeBeck, 2015; 
Richer, Bertrand, Vandermeerschen, & Roy, 2013; Schrager et al., 2014; Sherman et al., 
2007; Silva et al., 2013; Werb, Kerr, Lai, Montaner, & Wood, 2008). Therefore, individuals 
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with FCH exposure appear to be at highest risk for overdose. To mitigate fentanyl-related 
overdose risk, tailored prevention and harm reduction that engage young adults with more 
extensive NMPO and other drug use experience are needed. For example, a recent analysis 
of the same study sample found that fewer than half of study participants were aware of the 
Rhode Island Good Samaritan Law, which provides legal protections to individuals who 
witness an overdose (Evans, Hadland, Clark, Green, & Marshall, 2016). Campaigns to 
encourage young adults to call 911 in the event that they witness an overdose are needed. 
Programs to increase naloxone distribution and training to young adults who use prescription 
opioids non-medically are also needed (Marshall, Green, Yedinak, & Hadland, 2016).
To our knowledge, firsthand experiences with and attitudes toward FCH have not been 
explored in the US in recent decades. One study from 1983 found that, among 18 self-
identified users of fentanyl in California, many were not aware of the fentanyl contamination 
prior to use, and respondents perceived fentanyl contamination to increase overdose risk 
(LaBarbera & Wolfe, 1983). These results are consisted with present findings. Of major 
public health concern is our finding that the majority of participants who reported FCH 
exposure had used it without knowing that their heroin was contaminated with fentanyl. To 
inform public health efforts that address FCH, future research should examine whether 
fentanyl contamination can be reliably identified prior to consumption (using rapid tests, for 
example) (Amlani et al., 2015).
There are some limitations to this study. First, as our analyses were derived from a pilot 
study, the sample size is relatively small, which may have resulted in type I or II error. 
Second, our study likely underestimates the proportion of young adult NMPO users who 
have experience with FCH because some participants may have used FCH without their 
knowledge; the experiences of these individuals are not reflected here. Third, our study 
relies on self-report, as we did not collect biological confirmatory data. Additional research 
using toxicological analysis is needed to determine the prevalence of and risk factors for 
fentanyl exposure among young adults who use drugs. Finally, reported confidence in ability 
to identify fentanyl-contaminated heroin may not be reliable, as interpretations of this item 
may have varied (i.e., identify visually prior to use vs. identify sensation following use); for 
this reason, the proportion of young adult NMPO users who have experience with FCH 
might also be overestimated. Given these limitations, the findings from this study should be 
interpreted as preliminary and warrant additional research. Nonetheless, our findings 
underscore the urgent need for effective overdose prevention in this vulnerable population.
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• 11% of sample reported recent exposure to fentanyl-contaminated heroin 
(FCH)
• FCH users reported greater and more extensive drug use experiences
• Most reported that FCH provides a better high than heroin
• All acknowledged that FCH use increases overdose risk
• Most were unaware that their heroin was contaminated with fentanyl prior to 
use
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